Table 1.
Patient and donors’ characteristics.
| Number of cases | 236 |
| Patients’ characteristics | N (%) |
| Median age [range] | 50 (17–71) |
| Age ≥50 years/≥60 years | 115 (49%)/57 (24%) |
| Male and female sex | 144 (61%)/92 (39%) |
| Female donor to male recipient | 64 (27%) |
| Underlying disease | |
| AML | 76 (32%) |
| MDS | 39 (17%) |
| ALL | 22 (9%) |
| Non-Hodgkin’s lymphoma | 39 (17%) |
| Hodgkin disease | 31 (13%) |
| CLL | 8 (3%) |
| CML or other MPS | 12 (5%) |
| Multiple myeloma | 5 (2%) |
| Biphenotypic acute leukemia | 2 (1%) |
| Aplasia | 1 |
| Prolymphocytic leukemia | 1 |
| Response at transplant | |
| Complete remission (first and second) | 130 (55%) |
| Third complete remission | 16 (7%) |
| Partial remission | 33 (14%) |
| Stable disease | 17 (7%) |
| Progression or refractory disease | 33 (14%) |
| Induction chemotherapy aplasia | 5 (2%) |
| Primary graft failure | 2 (1%) |
| Refined Disease Risk Index (rDRI) | |
| Low rDRI | 29 (12%) |
| Intermediate rDRI | 125 (54%) |
| High rDRI | 72 (31%) |
| Very High rDRI | 7 (3%) |
| Prior HSCT, num. (%) | 77 (33%) |
| Previous aloSCT | 27 (11%) |
| Conditioning regimen | |
| FluBu | 23 (10%) |
| FluBuCy | 87 (37%) |
| TBF | 121 (51%) |
| Other (FluCyTBI, FluATG) | 5 (2%) |
| Conditioning intensity | |
| Myeloablative | 75 (32%) |
| Reduced intensity | 161 (68%) |
| Stem cell source | |
| Peripheral blood stem cells | 191 (81%) |
| Bone marrow | 45 (19%) |
| GvHD prophylaxis following PTCy | |
| Cyclosporine with MMF | 115 (49%) |
| Tacrolimus | 121 (51%) |
| CD34 + cells infused (×106/kg)(median, range) | 5,4 (1.95–11.42) |
| Median follow-up in survivors, months (range) | 37 [1–82] |
| Donors’ characteristics | |
| Male and female sex | 132 (56%)/104 (44%) |
| Donor relationship with patient | |
| Mother/Father | 13 (6%)/23 (10%) |
| Son/Daughter | 61 (26%)/41 (17%) |
| Brother/Sister | 55 (23%)/39 (16%) |
| Other donors | 4 (2%) |
| Donor and recipient CMV IgG combination | |
| D+/ R + − | 112 (48%) |
| D−/R+ | 69 (29%) |
| D+/ R− | 29 (12%) |
| D−/R− | 25 (11%) |
AML acute myeloid MDS Myelodysplastic syndrome, ALL acute lymphoblastic leukemia, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, MPN myeloproliferative neoplasm, HSCT hematopoietic stem cell transplantation, AlloSCT allogeneic stem cell transplantation, FluBu fludarabine-busulfan, FluBuBy fludarabine-busulfan-cyclophosphamide, TBF thiotepa-fludarabine-busulfan, FluCyTBI fludarabine-cyclophosphamide-total body irradiation, FluATG fludarabine-ATG, GvHD graft versus host disease, PTCy post-transplantation cyclophosphamide, MMF mycophenolate mofetil, CMV cytomegalovirus, D donor, R recipient.